Experimental gene therapy targets Alzheimer's in High-Risk patients
NCT ID NCT03634007
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 34 times
Summary
This early-stage study tested a gene therapy called LX1001 in 15 people with a specific genetic form of Alzheimer's (APOE4 homozygotes). The main goal was to check safety and side effects over 52 weeks. Participants had mild cognitive impairment or mild to moderate dementia due to Alzheimer's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University
Durham, North Carolina, 27708, United States
-
K2 Medical Research
Maitland, Florida, 32751, United States
-
PPD- Orlando Research Unit
Orlando, Florida, 32806, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.